Abstract
Although a wealth of evidence supports the use of 3‐hydroxy‐3‐methylglutaryl coenzyme A (HMG‐CoA) reductase inhibitors (statins) in patients with clinically evident coronary artery disease, these agents are still underutilized. Statins are the most effective agents in reducing low‐density lipoprotein‐cholesterol among lipid‐lowering drugs, and studies have recently shown that they improve endothelial function and plaque stabilization, and induce regression of atherosclerotic lesions. This article reviews the most recent evidence and guideline recommendations supporting the use of statins in chronic stable angina pectoris and acute coronary syndromes.
Keywords: acute coronary syndromes, chronic stable angina, coronary artery disease, statins
Full Text
The Full Text of this article is available as a PDF (468.4 KB).
References
- 1. Fuster V, Fayad ZA, Badimon JJ: Acute coronary syndromes: Biology. Lancet 1999; 353: SII5–9 [DOI] [PubMed] [Google Scholar]
- 2. Falk E, Shah PK, Fuster V: Coronary plaque disruption. Circulation 1995; 92: 657–671 [DOI] [PubMed] [Google Scholar]
- 3. Corti R, Badimon JJ: Value or desirability of hemorheological‐hemostatic parameter changes as endpoints in blood lipid‐regulating trials. Curr Opin Lipidol 2001; 12: 629–637 [DOI] [PubMed] [Google Scholar]
- 4. Ganz P, Creager MA, Fang JC, McConnell MV, Lee RT, Libby P, Selwyn AP: Pathogenic mechanisms of atherosclerosis: Effect of lipid‐lowering on the biology of atherosclerosis. Am J Med 1996; 101: 4A10S–16S [PubMed] [Google Scholar]
- 5. Tamai O, Matsuoka H, Itabe H, Wada Y, Kohno K, Imaizumi T: Single LDL apheresis improves endothelium‐dependent vasodilatation in hypercholesterolemic humans. Circulation 1997; 95: 76–82 [DOI] [PubMed] [Google Scholar]
- 6. Luscher TF, Tanner FC, Noll G: Lipids and endothelial function: Effects of lipid‐lowering and other therapeutic interventions. Curr Opin Lipidol 1996; 7: 234–240 [DOI] [PubMed] [Google Scholar]
- 7. Corti R, Badimon JJ: Biologic aspects of vulnerable plaque. Curr Opin Cardiol 2002; 17: 616–625 [DOI] [PubMed] [Google Scholar]
- 8. Vaughan CJ, Gotto AM Jr, Basson CT: The evolving role of statins in the management of atherosclerosis. J Am Coll Cardiol 2000; 35: 1–10 [DOI] [PubMed] [Google Scholar]
- 9. Corti R, Fuster V, Badimon JJ: Pathogenetic concepts of acute coronary syndromes. J Am Coll Cardiol 2003; 41: S7–S14 [DOI] [PubMed] [Google Scholar]
- 10. Ambrose JA, Martinez EE: A new paradigm for plaque stabilization. Circulation 2002; 105: 2000–2004 [DOI] [PubMed] [Google Scholar]
- 11. Corti R, Fayad ZA, Fuster V, Worthley SG, Helft G, Chesebro JH, Mercuri M, Badimon JJ: Effects of lipid‐lowering by simvastatin on human atherosclerotic lesions: A longitudinal study by high‐resolution, non‐invasive MRI. Circulation 2001; 104: 249–252 [DOI] [PubMed] [Google Scholar]
- 12. Aikawa M, Rabkin E, Sugiyama S, Voglic SJ, Fukumoto Y, Furukawa Y, Shiomi M, Schoen FJ, Libby P: An HMG‐CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro. Circulation 2001; 103: 276–283 [DOI] [PubMed] [Google Scholar]
- 13. Corti R, Fuster V, Fayad ZA, Worthley SG, Helft G, Smith D, Weinberger J, Wentzel J, Mizsei G, Mercuri M, Badimon JJ: Lipid‐lowering by simvastatin induces regression of human atherosclerotic lesions: Two years'### follow‐up by high‐resolution noninvasive magnetic resonance imaging. Circulation 2002; 106: 2884–2887 [DOI] [PubMed] [Google Scholar]
- 14. Zhao XQ, Yuan C, Hatsukami TS, Frechette EH, Kang XJ, Maravilla KR, Brown BG: Effects of prolonged intensive lipid‐lowering therapy on the characteristics of carotid atherosclerotic plaques in vivo by MRI: A case‐control study. Arterioscler, Thromb, Vasc Biol 2001; 21: 1623–1629 [DOI] [PubMed] [Google Scholar]
- 15. Pitt B, Waters D, Brown WV, van Boven AJ, Schwartz L, Title LM, Eisenberg D, Shurzinske L, McCormick LS: Aggressive lipid‐lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revascularization Treatment Investigators. N Engl J Med 1999; 341: 70–76 [DOI] [PubMed] [Google Scholar]
- 16. Serruys PW, de Feyter P, Macaya C, Kokott N, Puel J, Vrolix M, Branzi A, Bertolami MC, Jackson G, Strauss B, Meier B: Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: A randomized controlled trial. J Am Med Assoc 2002; 287: 3215–3222 [DOI] [PubMed] [Google Scholar]
- 17. Walter DH, Fichtlscherer S, Britten MB, Auch‐Schwelk W, Schachinger V, Zeiher AM: Benefits of immediate initiation of statin therapy following successful coronary stent implantation in patients with stable and unstable angina pectoris and Q‐wave acute myocardial infarction. Am J Cardiol 2002; 89: 1–6 [DOI] [PubMed] [Google Scholar]
- 18. Jonasson L, Linderfalk C, Olsson J, Wikby A, Olsson AG: Systemic T‐cell activation in stable angina pectoris. Am J Cardiol 2002; 89: 754–756 [DOI] [PubMed] [Google Scholar]
- 19. Ridker PM, Rifai N, Pfeffer MA, Sacks FM, Moyé LA, Goldman S, Flaker GC, Braunwald E: Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. Circulation 1998; 98: 839–844 [DOI] [PubMed] [Google Scholar]
- 20. Kinlay S, Timms T, Clark M, Karam C, Bilodeau T, Ridker PM, Rifai N, Carlson W, Lloyd‐Jones DM, Johnstone M, Rubenstein J, Alexander S, Orav J, Stone PH: Comparison of effect of intensive lipid‐lowering with atorvastatin to less intensive lowering with lovastatin on C‐reactive protein in patients with stable angina pectoris and inducible myocardial ischemia. Am J Cardiol 2002, 89: 1205–1207 [DOI] [PubMed] [Google Scholar]
- 21. Waters DD, Hsue PY: What is the role of intensive cholesterol lowering in the treatment of acute coronary syndromes? Am J Cardiol 2001; 88: 7J–16J [DOI] [PubMed] [Google Scholar]
- 22. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, Langendorfer A, Stein EA, Kruyer W, Gotto AM Jr: Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. J Am Med Assoc 1998; 279: 1615–1622 [DOI] [PubMed] [Google Scholar]
- 23. Eto M, Kozai T, Cosentino F, Joch H, Luscher TF: Statin prevents tissue factor expression in human endothelial cells: Role of Rho/Rho‐kinase and Akt pathways. Circulation 2002; 105: 1756–1759 [DOI] [PubMed] [Google Scholar]
- 24. Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, Zeiher A, Chaitman BR, Leslie S, Stern T: Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: The MIRACL study: A randomized controlled trial. J Am Med Assoc 2001; 285: 1711–1718 [DOI] [PubMed] [Google Scholar]
- 25. Arntz HR, Agrawal R, Wunderlich W, Schnitzer L, Stern R, Fischer F, Schultheiss HP: Beneficial effects of pravastatin (±colestyramine/niacin) initiated immediately after a coronary event (the randomized L‐CAD Study). Am J Cardiol 2000; 86: 1293–1298 [DOI] [PubMed] [Google Scholar]
- 26. Stenestrand U, Wallentin L: Early statin treatment following acute myocardial infarction and 1‐year survival. J Am Med Assoc 2001; 285: 430–436 [DOI] [PubMed] [Google Scholar]
- 27. Heeschen C, Hamm CW, Laufs U, Snapinn S, Bohm M, White HD: Withdrawal of statins increases event rates in patients with acute coronary syndromes. Circulation 2002; 105: 1446–1452 [DOI] [PubMed] [Google Scholar]
- 28. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol In Adults (ATPIII). J Am Med Assoc 2001; 285: 2486–2497 [DOI] [PubMed] [Google Scholar]
- 29. Ornish D, Scherwitz LW, Billings JH, Brown SE, Gould KL, Merritt TA, Sparler S, Armstrong WT, Ports TA, Kirkeeide RL, Hogeboom C, Brand RJ: Intensive lifestyle changes for reversal of coronary heart disease. J Am Med Assoc 1998; 280: 2001–2007 [DOI] [PubMed] [Google Scholar]
- 30. de Lorgeril M, Salen P, Martin JL, Monjaud I, Delaye J, Mamelle N: Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: Final report of the Lyon Diet Heart Study. Circulation 1999; 99: 779–785 [DOI] [PubMed] [Google Scholar]
- 31. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries : Principal results from EUROASPIRE II Euro Heart Survey Programme. Eur Heart J 2001; 22: 554–572 [DOI] [PubMed] [Google Scholar]
- 32. Fonarow GC, Gawlinski A, Moughrabi S, Tillisch JH: Improved treatment of coronary heart disease by implementation of a Cardiac Hospitalization Atherosclerosis Management Program (CHAMP). Am J Cardiol 2001; 87: 819–822 [DOI] [PubMed] [Google Scholar]